Global Quetiapine Fumarate Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Quetiapine Fumarate Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Quetiapine Fumarate is an atypical antipsychotic drug used to treat psychiatric disorders such as schizophrenia, bipolar disorder and depression. It may be used alone or in combination with other psychiatric medications. It is taken orally, and is available only by prescription, under the supervision of a medical practitioner.
Quetiapine Fumarate report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Quetiapine Fumarate market is projected to reach US$ 136.4 million in 2034, increasing from US$ 159.7 million in 2022, with the CAGR of -2.2% during the period of 2024 to 2034. Demand from Adult and Others are the major drivers for the industry.
Europe is the largest Quetiapine Fumarate market with about 92% market share. China is follower, accounting for about 2% market share.
The key players are AstraZeneca, Intas, TAPI, Accord, Hexal, Dr.Reddy's, Lupin, Sun Pharmaceutical, Hunan Dongting Pharm, SuZhou NO.4 Phamaceutical Factory, Fuan Pharmaceutical, Zhejiang Supor Pharmaceuticals, Zhejiang Huahai Pharmaceutical etc. Top 3 companies occupied about 74% market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Quetiapine Fumarate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AstraZeneca
Intas
TAPI
Accord
Hexal
Dr.Reddy's
Lupin
Sun Pharmaceutical
Hunan Dongting Pharm
SuZhou NO.4 Phamaceutical Factory
Fuan Pharmaceutical
Zhejiang Supor Pharmaceuticals
Zhejiang Huahai Pharmaceutical
Segment by Type
Immediate Release Tablets
Extended Release Tablets
Adult
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Quetiapine Fumarate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Quetiapine Fumarate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Quetiapine Fumarate industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Quetiapine Fumarate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Quetiapine Fumarate introduction, etc. Quetiapine Fumarate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Quetiapine Fumarate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Quetiapine Fumarate report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Quetiapine Fumarate market is projected to reach US$ 136.4 million in 2034, increasing from US$ 159.7 million in 2022, with the CAGR of -2.2% during the period of 2024 to 2034. Demand from Adult and Others are the major drivers for the industry.
Europe is the largest Quetiapine Fumarate market with about 92% market share. China is follower, accounting for about 2% market share.
The key players are AstraZeneca, Intas, TAPI, Accord, Hexal, Dr.Reddy's, Lupin, Sun Pharmaceutical, Hunan Dongting Pharm, SuZhou NO.4 Phamaceutical Factory, Fuan Pharmaceutical, Zhejiang Supor Pharmaceuticals, Zhejiang Huahai Pharmaceutical etc. Top 3 companies occupied about 74% market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Quetiapine Fumarate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AstraZeneca
Intas
TAPI
Accord
Hexal
Dr.Reddy's
Lupin
Sun Pharmaceutical
Hunan Dongting Pharm
SuZhou NO.4 Phamaceutical Factory
Fuan Pharmaceutical
Zhejiang Supor Pharmaceuticals
Zhejiang Huahai Pharmaceutical
Segment by Type
Immediate Release Tablets
Extended Release Tablets
Segment by Application
Adult
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Quetiapine Fumarate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Quetiapine Fumarate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Quetiapine Fumarate industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Quetiapine Fumarate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Quetiapine Fumarate introduction, etc. Quetiapine Fumarate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Quetiapine Fumarate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices